

## PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/137723>

Please be advised that this information was generated on 2017-12-05 and may be subject to change.

Article

## Curcumin-Induced Heme Oxygenase-1 Expression Prevents H<sub>2</sub>O<sub>2</sub>-Induced Cell Death in Wild Type and Heme Oxygenase-2 Knockout Adipose-Derived Mesenchymal Stem Cells

Niels A. J. Cremers <sup>1</sup>, Ditte M. S. Lundvig <sup>1</sup>, Stephanie C. M. van Dalen <sup>2</sup>, Rik F. Schelbergen <sup>2</sup>, Peter L. E. M. van Lent <sup>2</sup>, Walter A. Szarek <sup>3</sup>, Raymond F. Regan <sup>4</sup>, Carine E. Carels <sup>1</sup> and Frank A. D. T. G. Wagener <sup>1,\*</sup>

<sup>1</sup> Department of Orthodontics and Craniofacial Biology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, PO Box 9101, 6500 HB Nijmegen, The Netherlands; E-Mails: niels.cremers@radboudumc.nl (N.A.J.C.); ditte.lundvig@radboudumc.nl (D.M.S.L.); carine.carels@radboudumc.nl (C.E.C.)

<sup>2</sup> Department of Rheumatology, Experimental Rheumatology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, PO Box 9101, 6500 HB Nijmegen, The Netherlands; E-Mails: stephanie.vandalen@radboudumc.nl (S.C.M.D.); rik.schelbergen@radboudumc.nl (R.F.S.); peter.vanlent@radboudumc.nl (P.L.E.M.L.)

<sup>3</sup> Department of Chemistry, Queen's University, Kingston, ON K7L 3N6, Canada; E-Mail: szarekw@chem.queensu.ca

<sup>4</sup> Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA 19107, USA; E-Mail: Raymond.regan@jefferson.edu

\* Author to whom correspondence should be addressed; E-Mail: frank.wagener@radboudumc.nl; Tel.: +31-24-3614082; Fax: +31-24-3540631.

External Editor: Anthony Lemarié

Received: 11 June 2014; in revised form: 11 September 2014 / Accepted: 23 September 2014 /

Published: 8 October 2014

---

**Abstract:** Mesenchymal stem cell (MSC) administration is a promising adjuvant therapy to treat tissue injury. However, MSC survival after administration is often hampered by oxidative stress at the site of injury. Heme oxygenase (HO) generates the cytoprotective effector molecules biliverdin/bilirubin, carbon monoxide (CO) and iron/ferritin by breaking down heme. Since HO-activity mediates anti-apoptotic, anti-inflammatory, and anti-oxidative effects, we hypothesized that modulation of the HO-system affects MSC survival. Adipose-derived MSCs (ASCs) from wild type (WT) and HO-2 knockout (KO) mice were

isolated and characterized with respect to ASC marker expression. In order to analyze potential modulatory effects of the HO-system on ASC survival, WT and HO-2 KO ASCs were pre-treated with HO-activity modulators, or downstream effector molecules biliverdin, bilirubin, and CO before co-exposure of ASCs to a toxic dose of H<sub>2</sub>O<sub>2</sub>. Surprisingly, sensitivity to H<sub>2</sub>O<sub>2</sub>-mediated cell death was similar in WT and HO-2 KO ASCs. However, pre-induction of HO-1 expression using curcumin increased ASC survival after H<sub>2</sub>O<sub>2</sub> exposure in both WT and HO-2 KO ASCs. Simultaneous inhibition of HO-activity resulted in loss of curcumin-mediated protection. Co-treatment with glutathione precursor *N*-Acetylcysteine promoted ASC survival. However, co-incubation with HO-effector molecules bilirubin and biliverdin did not rescue from H<sub>2</sub>O<sub>2</sub>-mediated cell death, whereas co-exposure to CO-releasing molecules-2 (CORM-2) significantly increased cell survival, independently from HO-2 expression. Summarizing, our results show that curcumin protects via an HO-1 dependent mechanism against H<sub>2</sub>O<sub>2</sub>-mediated apoptosis, and likely through the generation of CO. HO-1 pre-induction or administration of CORMs may thus form an attractive strategy to improve MSC therapy.

**Keywords:** adipose-derived mesenchymal stem cells; oxidative stress; apoptosis; heme oxygenase; carbon monoxide

---

## 1. Introduction

Administration of mesenchymal stem cells (MSCs) forms a promising novel adjuvant treatment to improve tissue repair [1–4]. MSCs have been shown to accelerate dermal wound healing and can regenerate diverse injured organs, such as kidney, lung and heart [5–9]. MSCs are a heterogeneous population of fibroblast-like, multipotent stem cells characterized by their ability to differentiate into mature cells of the mesodermal lineage, like osteoblasts, chondrocytes, adipocytes, endothelial cells, and myocytes, and into cells outside the mesodermal lineage, such as keratinocytes, and fibroblasts [3,10–12]. Adipose tissue forms an easy accessible source for isolating MSCs for the use in (autologous) regenerative medicine and may therefore be a better alternative than MSCs isolated from other sources, such as bone marrow (BM) [13–16]. These adipose-derived MSCs (ASCs) are abundantly present in adipose tissue, easy to isolate, and highly proliferative. In addition, they secrete extensively regenerative factors, such as hepatocyte growth factor, vascular endothelial growth factor, basic fibroblast growth factor, interleukin (IL)-6, -7, -8, and -11, and stromal cell-derived factor-1 (SDF-1) [14–16].

Despite the promising utilization of MSCs in regenerative medicine, the low survival after administration and the limited migration of MSCs to the site of injury limits their therapeutic efficacy [17,18]. Local administration to the site of injury may attenuate the problems with MSC migration. However, MSC administration in the vicinity of the injured tissue may also affect MSC survival, as the wound microenvironment harbors excessive levels of inflammatory and oxidative mediators, hypoxia, and limited blood flow [19]. Oxidative and inflammatory stresses are known causes of MSC death [17,18,20]. Cells have several mechanisms to protect themselves against inflammatory and oxidative insults, including cytoprotective enzyme systems (e.g., glutathione

S-transferase, dismutases, catalases, and peroxidases) or anti-oxidants (vitamin A, C, and E, urate, glutathione, and bilirubin) [21]. In addition, MSCs may upregulate anti-apoptotic and anti-oxidative genes [16,19]. Pre-induction of cytoprotective pathways in the ASCs may improve their therapeutic potential by protecting them against the harsh microenvironment [22,23].

The cytoprotective enzyme heme oxygenase (HO) is important for (stem) cell survival and functioning [17,18,24,25]. HO breaks down heme into biliverdin, free iron ( $\text{Fe}^{2+}$ ) and carbon monoxide (CO). Biliverdin (BV) is rapidly converted into bilirubin (BR) by biliverdin reductase [26,27]. The iron scavenger ferritin is co-induced by HO-derived iron and is important for protection against iron-mediated reactive oxygen species (ROS) formation [28]. Two distinct isoforms (HO-1 and HO-2) exist. HO-2 is mainly constitutively expressed whereas HO-1 is highly inducible by a variety of patho-physiological stimuli, such as free heme, cytokines, hypoxia, and oxidative stress [29]. HO-2 is responsible for maintaining normal metabolic cellular functions, and regulating physiological levels of ROS [30–32].

Induction of HO-1 has been demonstrated to improve MSC therapy *in vivo* by improving tissue functioning of the damaged organ, whereas inhibition of HO-activity worsened MSC therapy outcome in diverse pathologic conditions, such as ischemia reperfusion injury of the heart, pulmonary arterial hypertension, diabetes, and dermal wound healing [31,33–40]. It has been shown *in vitro* that HO-1 overexpression increases BM-derived MSC survival against oxidative stress, but the exact mechanism remains unknown [17,34]. By contrast, induced pluripotent stem cells (iPSCs) and murine embryonic fibroblasts (MEFs) derived from HO-1 knockout mice accumulate higher levels of intracellular ROS after exposure to oxidative stress [41,42]. Moreover, HO-1 KO iPSCs and MEFs are more sensitive to hydrogen peroxide ( $\text{H}_2\text{O}_2$ )-induced cell death [41,42]. Since, the effects of HO-1 are extensively studied in stem cells, we investigate here the role of the HO-2 isoform in protection against oxidative stress. HO-2 has been shown to act in a protective manner against inflammatory and oxidative injury and cell apoptosis in diverse cell types [43–51].

In the present study we postulated that HO-2 WT ASCs would be better protected against oxidative stress when compared to HO-2 deficient ASCs. Additionally, we aimed to investigate the role of HO-activity and HO-effector molecules BR/BV and CO on ASC survival after  $\text{H}_2\text{O}_2$ -induced oxidative stress.


## 2. Results and Discussion

### 2.1. Isolation and Characterization of Adipose-Derived MSCs (Mesenchymal Stem Cells) (ASCs)

ASCs were isolated from mouse (WT and HO-2 KO) adipose tissue around the inguinal lymph nodes and cultured in defined media as described here in Experimental Section 3. The cells adhered to plastic and had, as expected for ASCs, a fibroblast-like morphology. Passage three of the isolated cell populations were characterized for the expression of mesenchymal, endothelial, and hematopoietic markers by immunophenotyping (Figure 1a) and qPCR (Figure 1b). Surface antigen expression of the isolated cells, using flow cytometry, was consistent with literature data and our previous results [52]. The cells expressed ASC surface markers Sca-1, CD44, and CD105 and were negative for the exclusion markers CD117 (hematopoietic stem cells), CD11b (macrophages) (Figure 1a), and showed low expression of CD34 (endothelial/hematopoietic progenitor cells) [16,53–58]. No significant differences

in ASC marker expression was detected between WT and HO-2 KO ASCs. These phenotypic observations at the protein level were further corroborated at the mRNA level using common MSC markers (Figure 1b). The isolated cells expressed high mRNA levels of ASC markers Sca-1, CD29 [16,54–56,58], CD105, and CD106 [16,54], whereas cells were negative for exclusion markers CD11b, CD31 [16,53–57], CD34, hematopoietic marker CD45 [16,53–58], antigen-presenting cell marker CD86 [58], and CD117 showing low levels of mRNA expression, compared to housekeeping gene GAPDH. No significant difference in marker expression was found between WT and HO-2 KO ASCs. We conclude that the isolated cells are ASCs, since the marker expression profile corresponded well with literature data of earlier reported isolated murine ASCs.

**Figure 1.** Phenotypic analysis of isolated WT (wild type) and HO-2 KO ASCs. (a) Percentage of positive cells for ASC exclusion markers (negative) and ASC cell surface markers (positive) of isolated WT and HO-2 KO ASCs, measured using flow cytometry; (b) mRNA levels of negative and positive ASC markers of isolated WT and HO-2 KO ASCs, analyzed by qPCR and presented as  $2^{-\Delta Ct}$ . No significant differences were observed between in the expression of selected markers between WT and HO-2 KO ASCs using both flow cytometry and qPCR. Data represent mean  $\pm$  SD of three independent experiments.



## 2.2. H<sub>2</sub>O<sub>2</sub> Induces Cell Death in ASCs in a Dose-Dependent Manner Independently from HO-2 Expression


ASCs were exposed to increasing concentrations of H<sub>2</sub>O<sub>2</sub> (0–500  $\mu$ M) to investigate the effect of oxidative stress on ASC survival. H<sub>2</sub>O<sub>2</sub> is a strong oxidant that can cause cell death and apoptosis. Compared to other ROS, H<sub>2</sub>O<sub>2</sub> is a relatively long-lived molecule commonly used in models of oxidative stress [59]. Exposing cells to H<sub>2</sub>O<sub>2</sub> results in deleterious effects of hydroxyl and peroxy radicals on membrane lipids and proteins, resulting in loss of mitochondrial membrane potential, mitochondrial dysfunction, and eventually apoptosis [60,61].

ASCs were exposed for 24 h to increasing concentrations of H<sub>2</sub>O<sub>2</sub> and cell viability was assessed using the Alamar blue assay. This assay is based on the ability of metabolically active cells to convert the Alamar blue reagent into a fluorescent signal, which is directly proportional to the cellular viability. Damaged and non-viable cells have lower innate metabolic activity, and generate thus a proportionally lower signal.

ASC viability decreased gradually after exposure to increasing concentrations of 200–500  $\mu$ M H<sub>2</sub>O<sub>2</sub> for 24 h (Figure 2a). Exposure to doses of 250  $\mu$ M H<sub>2</sub>O<sub>2</sub> and higher had a significant cytotoxic effect

for both WT and HO-2 KO ASCs compared to controls (all  $p < 0.001$ ). No ASCs survived at concentrations of 450  $\mu\text{M}$   $\text{H}_2\text{O}_2$  and higher. In parallel, the amount of cells after 24 h treatment with  $\text{H}_2\text{O}_2$  were analyzed using the picogreen assay. This assay quantifies the amount of double stranded DNA and is directly proportional to the amount of cells. These results were similar and corroborated our findings with the Alamar blue assay. The amount of cells decreased significantly at  $\text{H}_2\text{O}_2$  concentrations of 250  $\mu\text{M}$  and higher, in a dose-dependent fashion for both WT and HO-2 KO ASCs (Figure 2b). After treatment with 350  $\mu\text{M}$   $\text{H}_2\text{O}_2$  24%  $\pm$  2.5% of WT and 19.5%  $\pm$  4.9% of HO-2 KO ASCs survived. At this concentration, we found increased apoptosis in WT and HO-2 KO ASCs as measured by the increased levels of phosphatidylserine flip-flop and nuclear staining, using Annexin V-FITC and propodium iodide (PI), respectively (see Figure S1). Surprisingly, no significant difference could be observed between WT and HO-2 KO ASCs in sensitivity towards  $\text{H}_2\text{O}_2$ -induced cell death at any measured concentration. This suggests that HO-2 does not protect against  $\text{H}_2\text{O}_2$ -induced ASC death. Probably, the HO-2-activity level in naïve ASCs is too low. Although HO-2 has been demonstrated to protect against a wide range of oxidative insults in diverse cells, the role of HO-2 may be cell and stressor dependent [43,44,46,49]. HO-2 can either protect or augment apoptosis [45,50]. In this setting, ASCs were not dependent on HO-2 for their protection against  $\text{H}_2\text{O}_2$ -induced cell death.

**Figure 2.** Survival and cell amount of isolated WT and HO-2 KO ASCs after exposure to increasing doses of  $\text{H}_2\text{O}_2$  (0–500  $\mu\text{M}$ ) for 24 h. (a) WT and HO-2 KO ASC survival and (b) amount of ASCs after  $\text{H}_2\text{O}_2$ -treatment were analyzed using the Alamar blue assay and picogreen assay, respectively. Doses of 250  $\mu\text{M}$   $\text{H}_2\text{O}_2$  and higher resulted in a significant decreased survival and, subsequently, lower cell amounts (all  $p < 0.001$ ) compared to untreated control. No significant differences were observed between WT and HO-2 KO ASCs at any concentration. A dose of 350  $\mu\text{M}$   $\text{H}_2\text{O}_2$  was chosen in further experiments to induce ASC death. Data represent mean  $\pm$  SD of three independent experiments with four samples per condition. \* is significant different from treated control. (\*\*\*)  $p < 0.001$ .



Based on the above data, 350  $\mu\text{M}$   $\text{H}_2\text{O}_2$  was chosen as cytotoxic dose since it offers an analytical window to assess whether the HO-system could mediate protection against oxidative stress-induced cell death in ASCs.

### 2.3. Can Curcumin Induce HO-1 Expression in ASCs?

Next, we studied if we could induce the expression of HO-1 in ASCs to provide protection against oxidative damage. Therefore, ASCs were treated with increasing curcumin concentrations for 24 h and *HO-1* gene transcription was subsequently assessed by qPCR (Figure 3a).

**Figure 3.** HO-1 mRNA and protein expression was induced with increasing doses of curcumin (0–25  $\mu$ M) for 24 h in isolated WT and HO-2 KO ASCs. **(a)** WT and HO-2 KO ASCs were treated with curcumin for 24 h and HO-1 mRNA expression was evaluated with qPCR, corrected for the housekeeping gene *GAPDH* and normalized to untreated control. HO-1 mRNA expression was significantly ( $p < 0.05$ ) induced at every concentration in comparison to untreated control. Data represent mean  $\pm$  SD of three independent experiments. No significant differences between WT and HO-2 KO ASCs were found; **(b)** WT and HO-2 KO ASCs were treated with curcumin for 24 h and HO-1 protein expression was evaluated with In-Cell Western (green:  $\beta$ -actin, and red: HO-1); **(c)** Quantification of the In-Cell Western signal, corrected for the amount of cells with  $\beta$ -actin and related to untreated control. HO-1 protein expression was significantly ( $p < 0.05$ ) induced at every concentration in comparison to untreated control. Data represent mean  $\pm$  SD of three independent experiments. Four samples were analyzed per condition. No significant differences between WT and HO-2 KO ASCs were found; **(d)** WT and HO-2 KO ASCs were untreated or treated with 10  $\mu$ M curcumin for 24 h and HO-1 protein expression was evaluated using immuno-fluorescent staining of chamberslides (green is HO-1, blue represents nuclear staining with DAPI). Data is representative of three independent experiments.







Figure 3. Cont.



Exposure to curcumin for 24 h induced HO-1 mRNA levels dose-dependently in WT and HO-2 KO ASCs compared to untreated control. No significant differences in HO-1 induction were found between the two genotypes.

Next, the HO-1 protein expression after treatment with different concentrations of curcumin was assessed using In-Cell Western (Figure 3b). HO-1 protein expression was quantified in relation to  $\beta$ -actin protein expression (Figure 3c). We observed that HO-1 protein expression was significantly and dose-dependently induced after 24 h treatment with increasing doses of curcumin compared to untreated control in both WT and HO-2 KO ASCs. HO-1 protein expression after induction with curcumin was not significantly different between WT and HO-2 KO ASCs at any of the used concentrations. Furthermore, a plateau in expression was reached as we did not detect any difference in HO-1 expression levels at concentrations of 10 and 15  $\mu$ M. For our next experiments we used 10  $\mu$ M curcumin, since high concentrations of curcumin (25  $\mu$ M) may cause cell death *in vitro* [62]. Treatment with 10  $\mu$ M curcumin did not result in cytotoxic effects and induced HO-1 mRNA expression 20-fold and HO-1 protein levels roughly 7-fold compared to untreated cells.

The HO-1 protein induction in WT and HO-2 KO ASCs was also measured using immuno-fluorescent staining (Figure 3d). In accordance with the mRNA and In-Cell Western expression data we demonstrated that HO-1 protein expression was highly up-regulated in ASCs from both genotypes after treatment with 10  $\mu$ M curcumin in comparison with untreated control.

There were no significant differences observed in HO-1 induction at either mRNA or protein level between WT and HO-2 KO ASCs after treatment with 10  $\mu$ M curcumin. We demonstrated that curcumin acts as a potent inducer of HO-1 in both WT and HO-2 KO ASCs after treatment for 24 h.

#### 2.4. HO-1 Inducer Curcumin Protects against $H_2O_2$ -Mediated ASC Death in a HO-2 Independent Manner


Pre-conditioning of MSCs with cytoprotective factors can improve MSC survival against several injurious stressors *in vitro*, such as serum-free conditions, hypoxia and oxidative stress [14,63]. It has been shown that pre-conditioning of MSCs with melatonin [61], NO-donor *S*-nitroso *N*-acetylpenicillamine (SNAP) [64], or overexpression of transcription factor nuclear factor-erythroid 2-related factor 2 (nrf2) [18] can prevent MSC death caused by  $H_2O_2$ . Interestingly, these



preconditioning factors are also potent inducers of HO-1 [65–67]. Since HO-1 can protect against oxidative stress in diverse models [17,34], we investigated if HO-1 induction can also protect against oxidative stress-induced ASC death. Since HO-1 transfection is difficult to introduce safely into the clinic, we investigated the use of the safe pharmaceutical HO-1 inducer curcumin. Curcumin is a natural product that is already used in daily life as a spice in the Indian kitchen [68,69], acts as an anti-oxidant [70], and provides protection against a wide variety of diseases and conditions [71–73]. Moreover, a protective role for polyphenols, including curcumin, on BM-derived MSC survival against oxidative stress was recently demonstrated [21]. However, any relation to the HO-system was not investigated, and the survival was thought to relate to the induction of ROS-reducing enzymes glutathione peroxidase (GPX) and catalase [21].

In order to investigate the role of curcumin on H<sub>2</sub>O<sub>2</sub>-induced cell death in more detail, ASCs were pre-treated for 24 h with 10 μM of curcumin followed by co-treatment with 350 μM H<sub>2</sub>O<sub>2</sub> for 24 h after which the cell viability was assessed using the Alamar blue assay. Pre-conditioning with curcumin significantly improved ASC survival during oxidative stress (Figure 4). Pre-treatment with 10 μM curcumin increased ASC survival 2.7- and 3.6-fold in WT (Figure 4a) and HO-2 KO ASCs (Figure 4b), respectively, compared to cells exposed to solely 350 μM H<sub>2</sub>O<sub>2</sub>. This is further supported by picogreen data that showed significantly more WT and HO-2 KO ASCs when pre-treated with curcumin (Figure S2). Vehicle control ethanol did not increase ASC survival and cell amount compared to H<sub>2</sub>O<sub>2</sub>-treated control cells. Since we found that curcumin acts as a strong inducer of HO-1 this suggests a possible role for HO-1 in ASC survival from oxidative stress.

**Figure 4.** Curcumin treatment rescues WT and HO-2 KO ASCs against H<sub>2</sub>O<sub>2</sub>-induced cell death. **(a)** WT ASC and **(b)** HO-2 KO ASC survival after 24 h pre-treatment with curcumin, vehicle control, or untreated (control) and 24 h co-treatment together with 350 μM H<sub>2</sub>O<sub>2</sub> following an Alamar blue assay and fluorimetric quantification, related to untreated control. Vehicle consisted of 0.5% ethanol (curcumin solvent) in culture media. \* is significant different from H<sub>2</sub>O<sub>2</sub>-treated control. (\*  $p < 0.05$ , \*\*\*  $p < 0.001$ ). Data is representative of three independent experiments and presents mean ± SD. For each condition six samples were analyzed.



Interestingly, transient overexpression of the human *HO-1* gene in BM-derived MSCs has been shown to protect against oxidative stress-induced cell death [17,34]. HO-1 transfected BM-derived MSCs were more resistant to cell death than non-transfected MSCs after exposure to H<sub>2</sub>O<sub>2</sub> [34]. Survival at 500 μM H<sub>2</sub>O<sub>2</sub> for two hours was higher after HO-1 transfection and HO-1 induction could thus protect BM-MSCs to a short exposure of high concentrations H<sub>2</sub>O<sub>2</sub>. At a lower concentration of H<sub>2</sub>O<sub>2</sub> but longer treatment time with H<sub>2</sub>O<sub>2</sub> we showed also protection for ASC following curcumin exposure, suggesting that HO-1 induction plays a role. We further investigated the downstream mechanism of protection after pre-conditioning with the clinically more relevant curcumin towards an exposure of H<sub>2</sub>O<sub>2</sub> for 24 h.

In summary, curcumin provides similar protection against H<sub>2</sub>O<sub>2</sub>-induced cell death both in WT and HO-2 KO ASCs. A possible involvement of HO-activity will be further evaluated.


### 2.5. Is Rescue from H<sub>2</sub>O<sub>2</sub>-Induced ASC Death by Curcumin Mediated by HO-Activity?

We have shown that curcumin can protect against ASC death caused by oxidative stress. Since we demonstrated that curcumin induces HO-1 expression in ASCs, we next examined whether the protective mechanism of curcumin is HO-dependent using a specific HO-activity inhibitor. We used the synthetic isozyme-selective non-porphyrin HO-activity inhibitor QC-15 to test its effect on ASC survival. QC-15 is an imidazole-dioxolane compound that binds to the distal side of the heme-binding place in the HO protein and is a highly selective HO-1 activity inhibitor and has less potency to inhibit HO-2 activity [74–77].

Specifically, we investigated whether HO-1 activity inhibition would reduce ASC survival, and in addition, if the protecting effect of curcumin could be attenuated by co-treatment with QC-15. ASCs were therefore pre-incubated for 24 h with HO-activity modulators followed by a co-treatment with 350 μM H<sub>2</sub>O<sub>2</sub> for 24 h, after which the ASC-survival was assessed using the Alamar blue assay.

Surprisingly, we found that co-exposure of 50 μM QC15 together with H<sub>2</sub>O<sub>2</sub> did not influence cell survival when compared to cells treated with only H<sub>2</sub>O<sub>2</sub> in both WT and HO-2 KO ASCs (Figure 5). This suggests that the basal levels of both HO-1 and HO-2 are not sufficient for protection. However, the increased survival of ASCs after 10 μM curcumin treatment, and subsequent induced HO-1 expression, against H<sub>2</sub>O<sub>2</sub> was completely abrogated ( $p < 0.001$ ) following co-treatment with 50 μM QC15 in both WT as HO-2 KO ASCs. These results clearly demonstrate the protective potential of pre-induction of HO-1-activity in preventing oxidative stress-induced ASC death. Surprisingly, this is likely independent from HO-2, since no differences in survival were found between WT and HO-2 KO ASCs. In addition, picogreen data also showed a decline in cell amount after co-treating curcumin with QC15 (Figure S2). However, this decrease in cell amount was not always significant for both WT and HO-2 KO ASCs in replicate experiments. Similar protective effects of HO-activity from injurious insults have also been demonstrated in other cell lines [78,79]. Induction of HO-activity by flavonoid baicalcin and HO-1 transfection protected raw 264.7 macrophages and vascular smooth muscle cells against H<sub>2</sub>O<sub>2</sub>-induced cell death. Also here, inhibition of HO-activity attenuated this protection [78,79].

**Figure 5.** Inhibition of HO-activity abrogated the protective effect of curcumin against H<sub>2</sub>O<sub>2</sub>-induced cell death in isolated WT and HO-2 KO ASCs. **(a)** WT ASC and **(b)** HO-2 KO ASC survival after 24 h pre-treatment with HO-modulators or untreated (control) and 24 h co-treatment together with 350 μM H<sub>2</sub>O<sub>2</sub> as measured by Alamar blue assay and fluorimetric quantification, related to untreated control. Vehicle consisted of 0.5% ethanol (curcumin solvent) in culture media. \* is significant different from treated control. (\*  $p < 0.05$ , and \*\*\*  $p < 0.001$ ). Data represent a representative of three independent experiments and present mean ± SD. For each condition six samples were analyzed.




Thus, curcumin-induced protection against H<sub>2</sub>O<sub>2</sub>-induced ASC death acts via induction of HO-1, whereas inhibition of HO-activity abrogates this protective effect.

## 2.6. Do Anti-Oxidants Bilirubin, Biliverdin, and NAC Rescue from H<sub>2</sub>O<sub>2</sub>-Induced ASC Death?

Since HO-activity protects against H<sub>2</sub>O<sub>2</sub>-mediated cell death, we investigated whether the anti-oxidative properties of HO-effector molecules BR and BV, or anti-oxidant *N*-acetylcysteine (NAC) could mediate a protective effect. It has previously been reported that NAC; a precursor of glutathione (GSH) synthesis, and BR and BV can protect cells from ROS-induced cell death [62,80,81]. GSH serves as electron donor for glutathione peroxidase to catalyze the reduction of H<sub>2</sub>O<sub>2</sub> into H<sub>2</sub>O, and is together with catalase the only defense available to metabolize H<sub>2</sub>O<sub>2</sub> [82,83]. GSH and BR are both prominent endogenous anti-oxidant molecules, protecting against oxidative stress on a complementary basis and have a distinct antioxidant mechanism [84]. Therefore, we investigated the possible contribution of the different anti-oxidants NAC, BR, and BV on ASC survival. Pre-treatment for 24 h with 10 μM BR, 10 μM BV, and 6 mM NAC and co-exposure for another 24 h with 350 μM H<sub>2</sub>O<sub>2</sub> was performed to investigate the effects on ASC survival. This was assessed using the Alamar blue assay. Anti-oxidant NAC significantly increased cell survival compared to H<sub>2</sub>O<sub>2</sub>-treated control in WT and HO-2 KO ASCs 6.3- and 7.1-fold, respectively (Figure 6). NAC may also influence mitochondrial biogenesis [85], and thus might cause bias in the Alamar blue assay, since this assay is a measure of mitochondrial activity. However, NAC significantly increased the cell amount compared to H<sub>2</sub>O<sub>2</sub>-treated control as confirmed by the picogreen assay, suggesting that NAC does not only promote mitochondrial biogenesis but also cell

survival (Figure S2). Since NAC can interfere with several cell viability test methods [86], we corroborated that cell-free NAC containing media did not influence the Alamar blue signal (data not shown). Increasing GSH formation results in a more reduced intracellular environment, and promotes cell proliferation and survival [87]. NAC has been demonstrated to promote the proliferation of different cell types, including adipose derived stem cells and BM stromal cells [88,89]. Surprisingly, the anti-oxidants BR and BV did not improve ASC survival in both WT and HO-2 KO ASCs (Figures 6 and S2). Treatment with BR and BV in the absence of H<sub>2</sub>O<sub>2</sub> did not result in increased cell death, as measured by the Alamar blue assay (data not shown). The observed differences between NAC and BR/BV may be related to the different targets that these anti-oxidants have [84]. GSH is hydrophilic and protects mainly water-soluble proteins in the cytosol, while BR and BV are more lipophilic and protect against lipid peroxidation of cell membranes [84]. The microenvironment largely determines which mechanism is needed to sustain redox homeostasis [87]. H<sub>2</sub>O<sub>2</sub> can easily penetrate the cell membrane, and form hydroxyl radicals with intracellular metal ions. Treatment with H<sub>2</sub>O<sub>2</sub> results in cytosolic release of cytochrome c as well as activating caspase-9 and caspase-3 and works through the intrinsic/mitochondrial apoptotic pathway in several cell types, including MSCs [90–95]. And hence, H<sub>2</sub>O<sub>2</sub> scavenging is likely more dependent on GSH, rather than BR and BV.

**Figure 6.** Survival of WT and HO-2 KO ASC against H<sub>2</sub>O<sub>2</sub>-induced cell death after treatment with anti-oxidants. **(a)** WT ASC and **(b)** HO-2 KO ASC survival after 24 h pre-treatment with anti-oxidant NAC or HO-effector molecules BR and BV, and 24 h co-treatment together with 350 μM H<sub>2</sub>O<sub>2</sub> following an Alamar blue assay and fluorimetric quantification, related to untreated control. \* is significant different from treated control. (\*\*\*)  $p < 0.001$ . Data represent a representative of three independent experiments and present mean ± SD. For each condition six samples were analyzed. NAC: *N*-acetylcysteine; BR: Bilirubin; BV: Biliverdin.



Our results show that H<sub>2</sub>O<sub>2</sub>-induced cytotoxicity can be prevented by NAC, but not BR and BV. This suggests that HO-1-mediated ASC survival following H<sub>2</sub>O<sub>2</sub>-treatment is independent from HO-effector molecules BR and BV and independent of intrinsic HO-2 expression.

### 2.7. Does HO-Effector Molecule Carbon Monoxide Influence H<sub>2</sub>O<sub>2</sub>-Induced ASC Death?


Since we have shown that HO-activity is responsible for ASC survival, and is independent from the effector molecules BR and BV, we next investigated the effects of the HO-effector molecule CO. The HO-effector molecules also provide protection through different mechanisms; BR and BV are anti-oxidants, whereas CO is thought to work on regulating downstream signaling pathways. Furthermore, CO may produce mitochondrial ROS initiating intracellular protective signaling pathways and maintain cells in homeostasis [96–98].

In order to determine whether CO could mediate the HO-induced protection against H<sub>2</sub>O<sub>2</sub>-induced ASC death, we treated the cells with CO releasing molecules-2 (CORM-2), and found that this resulted in significantly higher ASC survival in WT and HO-2 KO ASCs compared to H<sub>2</sub>O<sub>2</sub>-exposed ASCs (Figure 7). The absence of HO-2 expression in the ASCs in our experimental setup did not have any significant influence on its survival against H<sub>2</sub>O<sub>2</sub>-induced cell death. In addition, CORM-2 control and solvent control (DMSO) treated cells showed no protection and survival were comparable to cells treated with H<sub>2</sub>O<sub>2</sub>. Thus, the HO-mediated protection mechanism is likely dependent on the effects of CO-release. This was partly confirmed by our picogreen data (Figure S2). Here, we found that more cells were present after CORM-2 treatment in WT ASCs ( $p < 0.001$ ) exposed to H<sub>2</sub>O<sub>2</sub>. However, in HO-2 KO ASCs this protective effect of CORM-2 on cell amount was not always significant in replicate experiments. A decrease in viability may therefore not always mean a decrease in cell amount. In line with our results, Lin *et al.* [78] also demonstrated that CO, but not BR and BV administration inhibited H<sub>2</sub>O<sub>2</sub>-induced cytotoxicity in macrophages, suggesting that CO is responsible for the protective effect caused by HO-1 overexpression in both macrophages and ASCs. Furthermore, the ruthenium-based CORM-2 and CORM-2 control have been demonstrated to be potent inducers of HO-1, which could have further boosted the protective effects of CORM-2 via a positive feedback loop [99,100]. Preliminary experiments show indeed induction of HO-1 following exposure to CORM-2 and to a lower extent for CORM-2 control. This positive feedback between HO-1 and CO (and nrf-2) has previously been demonstrated in hepatocytes [101] and vascular endothelium cells [102].

The down-stream protective effects of CO can be mediated by several protective signaling pathways. Pre-treatment with CORM-2 increases mitochondrial ROS signaling, which leads to pre-conditioning of the cells, making them more resistant to secondary stresses with H<sub>2</sub>O<sub>2</sub> [103,104]. In addition, CO may activate diverse other downstream signaling pathways, including nrf-2, guanylate cyclase, p38 mitogen-activated protein kinase (MAPK), PI3K-Akt, and iNOS [98,102,104]. Finally, CO can reduce the production of ROS in cells treated with H<sub>2</sub>O<sub>2</sub>, probably by preventing the formation of hydroxyl radicals by binding to ionized iron [105].

More research is warranted to unravel the exact mechanism by which CORM-2 exerts its protective effects. These results suggest that CO is responsible for the observed HO-mediated ASC survival from oxidative stress.

**Figure 7.** CORM-2 increases WT and HO-2 KO ASC survival against H<sub>2</sub>O<sub>2</sub>-induced cell death. **(a)** WT ASC and **(b)** HO-2 KO ASC survival after 24 h pre-treatment with CORM-2, or its controls, and 24 h co-treatment together with 350  $\mu$ M H<sub>2</sub>O<sub>2</sub> following an Alamar blue assay and fluorimetric quantification, related to untreated control. Vehicle consisted of 0.1% DMSO (CORM-2 and CORM-2 control solvent) in culture media. \* is significant different from treated control. (\*\*\*)  $p < 0.001$ . Experiments are performed in triplicate with samples in sextet. Representative graph is shown. Data are presented as mean  $\pm$  SD. CORM-2: CO-releasing molecule-2.



## 2.8. In Summary

Administering MSCs forms a promising therapy following pathologic tissue injury. However, the poor survival of MSCs following administration limits their therapeutic efficacy. In this study, we demonstrated that exposure of adipose-derived MSCs (ASCs) to oxidative stress results in ASC death and that induction of the HO-system by curcumin can attenuate this. Simultaneous inhibition of HO-activity could abrogate the protective effects of curcumin, demonstrating an essential role for HO-1. We found that also NAC improved ASC survival, whereas BR or BV did not demonstrate a protective effect, and thus suggest differential anti-oxidative protective mechanisms. Since administration of the HO-effector molecule CO also attenuated H<sub>2</sub>O<sub>2</sub>-induced ASC death, it is likely that CO mediates in part the protective effects of HO-1 induction. All these effects were independent from HO-2 expression, as the results for WT and HO-2 KO ASCs were similar.

## 2.9. Clinical Relevance

Increased levels of ASCs at the site of injury may ameliorate tissue repair by their differentiation capacity and the excretion of paracrine factors into the tissue environment further promoting wound repair [106–109]. The clinical relevance of HO-1 induction in MSCs is further supported using *in vivo* models of tissue injury demonstrating improved MSC survival and tissue function [33–35,109–112].

Our results further emphasize the important roles of HO-1 and CO as targets for improved ASC survival and therapy in tissue repair. We also show that HO-2 expression is less important in mediating protection against oxidative insults in ASCs.

### 3. Experimental Section

#### 3.1. Reagents

Biliverdin and bilirubin were purchased from Frontier Scientific, Carnforth, UK. Curcumin, *N*-acetyl-L-cysteine (NAC), tricarbonyldichlororuthenium(II)dimer (CO releasing molecule: CORM-2), and Ruthenium(III)chloride (CORM-2 control) were purchased from Sigma-Aldrich, Zwijndrecht, The Netherlands. Biliverdin, and bilirubin were prepared by dissolving this together with Trizma base in 2 mL 0.1 M NaOH and 5 mL H<sub>2</sub>O. The pH was adjusted to pH 8 with HCl, and further diluted till 10 mL with H<sub>2</sub>O. An end concentration of 1 μM was used in the experiments [76]. Curcumin was dissolved in 99.5% ethanol at a concentration of 2 mM. The stock solutions were filter-sterilized (0.2 μm filter), protected from light and directly used at a final concentration of 5–15 μM. NAC was dissolved in phosphate buffered saline (PBS) and used at a final concentration of 6 mM [76]. CORM-2, and CORM-2 control were both dissolved in DMSO, and diluted 1000× in work solution to 50 μM. QC15 was produced by Dr. Szarek; Department of Chemistry, Queen's University, Kingston, ON, Canada [62,113], and used at an end concentration of 50 μM. Hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) (30%) was purchased from Merck, Hohenbrunn, Germany.

#### 3.2. Mice

The Committee for Animal Experiments of the Radboud University Nijmegen approved all procedures involving animals. Mice (HO-2 KO and WT with a mixed C57BL/6\_129/Sv background [114]) of 6–12 weeks in age were housed under standard specific pathogen-free housing conditions.

#### 3.3. Isolation and Culture of ASCs

Adipose-derived mesenchymal stem cells (ASCs) were routinely isolated from WT and HO-2 KO mice as described previously [52]. In brief, adipose tissue surrounding the mouse inguinal lymph nodes were isolated and cut up using scalpels, followed by 30 min of incubation at 37 °C with digestion buffer (30 wt/v %, fat/digestion buffer). Digestion buffer consisted of complete ASC culture media: DMEM/F12 (Gibco, New York, NY, USA) supplemented with 2% Penicillin/Streptomycin (Pen/Strep) (Invitrogen, Carlsbad, CA, USA), 0.5% Amphotericin B (Invitrogen), 16 μM Biotin (Sigma Aldrich, St. Louis, MO, USA), 18 μM Panthotenic Acid (Sigma Aldrich), 100 μM Ascorbic Acid (Sigma Aldrich), and 10% Newborn Calf Serum (Sigma Aldrich), with additionally 2 mg/mL collagenase A (Roche, Woerden, The Netherlands) and 2 wt/v % Bovine Serum Albumin (Sigma Aldrich). Digested adipose tissue was filtered over a 25 μm filter and the filtrate was centrifuged 10 min at 500× g. Pellet was resuspended in 1 mL culture media and red blood cells were lysed with 7 mL ammonium chloride solution (Stem Cell technologies, Grenoble, France). Next, the cells were counted using the Beckman Coulter Z2 (Beckman Coulter, Woerden, The Netherlands: >4 μm <25 μm) and seeded at a concentration of 8000 cells/cm<sup>2</sup> in complete culture media.

Genotypes were confirmed using qPCR showing that HO-2 KO ASCs were in contrast to WT ASCs, negative for HO-2 mRNA expression (data not shown). In order to phenotypically analyze the ASC population we further used a panel of specific ASC markers and exclusion markers expressed on



macrophages, endothelial cells, and hematopoietic cells to exclude non-ASCs. Cells (passage 3) isolated from WT and HO-2 KO mice were tested for six different stem cell markers using flow cytometry. The adipose-derived cells were stained with the MSC markers Sca-1, CD44 and CD105 (BD Bioscience, Breda, The Netherlands; Biolegend, San Diego, CA, USA and eBioscience, San Diego, CA, USA, respectively) and exclusion markers CD11b, cKit and CD34 (Biolegend; BD Bioscience and eBioscience, respectively). In addition, we chose a subset of cell markers for Quantitative Reverse-Transcriptase PCR (qPCR), analysis (Table 1). ASCs up to passage number 5 were used for the different experiments.

**Table 1.** Primer sequences of mouse ASC cell surface markers and cytoprotective enzymes.

Gene Name	Sense	Antisense
<i>Cell Surface Marker</i>		
<i>CD45</i>	5'-GACAGAGTGCAAAGGAGACC-3'	5'-ATCACTGGGTGTAGGTGTTTG-3'
<i>Sca1</i>	5'-AGCAGTTATTGTGGATTCTC-3'	5'-TAGTACCCAGGATCTCCATAC-3'
<i>CD105</i>	5'-TTGTACCCACAACAGGTCTC-3'	5'-GGTGGTAAACGTCACCTCAC-3'
<i>CD29</i>	5'-AAATTGAGATCAGGAGAACCAC-3'	5'-GGTAATCTTCAGCCCTCTTG-3'
<i>CD11b</i>	5'-CTGGTCACAGCCCTAGCC-3'	5'-TTTGCATTCTCTTGGGAAGGTC-3'
<i>CD31</i>	5'-CTGGTGCTCTATGCAAGC-3'	5'-GCTGTTGATGGTGAAGGAG-3'
<i>CD34</i>	5'-TGAGTCTGCTGCATCTAAATAAC-3'	5'-CTCATTGGTAGGAACTGATGG-3'
<i>CD117</i>	5'-GCCAGACAGCCACGTCTC-3'	5'-CTGATTGTGCTGGATGGATG-3'
<i>CD106</i>	5'-CGTGGACATCTACTCTTCC-3'	5'-TGTAAGTGGTAAATGTCTGG-3'
<i>CD86</i>	5'-GTCAGTGATCGCCAACTTC-3'	5'-TCTTCTTAGGTTTCGGGTGAC-3'
<i>Housekeeping Gene</i>		
<i>GAPDH</i>	5'-GGCAAATTCAACGGCACA-3'	5'-GTTAGTGGGGTCTCGCTCCTG-3'
<i>Cytoprotective Enzymes</i>		
<i>HO-1</i>	5'-CAACATTGAGCTGTTTGAGG-3'	5'-TGGTCTTTGTGTTCTCTGTC-3'
<i>HO-2</i>	5'-AAGGAAGGGACCAAGGAAG-3'	5'-AGTGGTGGCCAGCTTAAATAG-3'

### 3.4. Heme Oxygenase Protein Expression by in-Cell Western

ASCs were cultured in a 96-well plate, fixated with 4% paraformaldehyde (PFA) for 15 min, and permeabilized with 0.1% Triton X-100 in PBS for 30 min. The cells were blocked with 5% ELK (Campina skimmed milk powder) in PBS for 90 min. First antibody (rabbit-anti-HO-1 polyclonal antibody; Stressgen Biotechnologies, Victoria, BC, Canada; cat# SPA895: 6.7 µg/mL in 2.5% ELK and mouse-anti-β-actin monoclonal antibody; Sigma Aldrich, St. Louis, MO, USA; cat# A5441: 5 µg/mL in 2.5% ELK) treatment was performed overnight at 4 °C. Secondary antibody treatment (goat-anti rabbit Alexa fluor 680; Invitrogen: Molecular Probes, Eugene, OR, USA, 2.5 µg/mL in 2.5% ELK, and goat-anti-mouse InfraRedDye 800; Rockland, Gilbertsville, PA, USA, 1.25 µg/mL in 2.5% ELK) was performed for one hour. The plate was measured using the Odyssey Imager with detection in both 700 and 800 nm channels at an intensity of 5 and 7.5, respectively, and was analyzed using Odyssey software (LI-COR Biosciences, Lincoln, NE, USA; version 2.1.12). The amount of HO-1 protein expression was quantified in relation to the expression of β-actin protein. Since the Western blot shows only one specific single band following induction with curcumin, the SPA895 antibody specifically recognizes HO-1 (see Figure S3). Therefore, we used this antibody for immuno-fluorescent and In-Cell Western techniques.

### 3.5. Heme Oxygenase Protein Expression by Immuno-Fluorescent Staining

HO-1 protein expression was also evaluated by immuno-fluorescent staining of ASCs treated with curcumin on plastic chamberslides (Nunc, Lab-Tek: Permanox 8-well chamberslides: Thermo Scientific, Rochester, NY, USA). In the chambers, cells were fixated with 4% PFA for 15 min, permeabilized with 0.5% Triton X-100 in PBS for 20 min, and washed with 0.05% Tween in PBS (PBS-T). Next, the cells were incubated with blocking buffer consisting of 2% bovine serum albumin, 2% normal goat serum, 0.1% Triton X-100, 0.05% Tween, and 100 mM glycine in PBS for 30 min. First antibody (Rb-a-HO-1; Stressgen Biotechnologies; Cat# SPA895) was diluted 1:600 in blocking buffer without glycine and incubated on cells for 60 min. After washing with PBS-T, cells were incubated with secondary antibody goat-anti-rabbit alexa 594 (Life Technologies, Bleiswijk, The Netherlands, cat# A-11037 diluted 1:200 in blocking buffer without glycine) for 60 min. Next, the cells were washed with PBS-T, followed by washing with PBS, and nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI) for 10 min. Finally, cells were washed with PBS, 1:1 PBS:MQ, and MQ and sealed with 1,4-diazabicyclo[2.2.2]octaan (DABCO). The Zeiss Imager Z1 microscope (Zeiss, Sliedrecht, The Netherlands) was used to make fluorescent pictures of the cells using Axiovision software version 4.8 (Zeiss).

### 3.6. mRNA Isolation and Quantitative-Reverse-Transcriptase-PCR

Cells were lysed and homogenized in TRIzol (Invitrogen) and RNA was further extracted with the RNeasy mini kit (Qiagen, Venlo, The Netherlands). DNase treatment (Qiagen: RNase-Free DNase Set) was performed between the first washing steps with RW1 buffer. RNA concentration was determined using the nanodrop 2000 spectrophotometer (Thermo Scientific). For the reverse transcriptase treatment 1 µg sample RNA together with total RT mix (iScript cDNA Synthesis kit from Bio-Rad Laboratories, Veenendaal, The Netherlands) in a total volume of 20 µL was incubated for 5 min at 25 °C, 30 min at 42 °C and 5 min at 85 °C. Hereafter the cDNA was diluted 10× and used for Quantitative Reverse-Transcriptase PCR (qPCR), using CFX96 Real-Time System (Bio-Rad Laboratories). The reaction was performed in 25 µL containing 5 µL cDNA, 0.6 µM primers, 12.5 µL iQ SYBR Green Supermix (Bio-Rad Laboratories). After incubation of 3 min, amplification was carried out for 40 cycles of 15 s at 95 °C and 30 s at 60 °C. The melting temperature of the products was defined to indicate amplification specificity. All values were normalized to the housekeeping gene *GAPDH*. Data of the ASC characterization were presented as  $2^{-\Delta Ct}$ . HO-1 mRNA expression was evaluated after treatment with curcumin for 24 h and related to untreated control ( $2^{-\Delta\Delta Ct}$ ). All used primers are summarized in Table 1.

### 3.7. Determination of Cell Viability

Cells were seeded into a 96 wells plate at 2000 cells/well and after overnight culturing of the cells were pre-treated with HO-activity modulators or HO-system related molecules for 24 h, followed by a co-treatment with 350 µM hydrogen peroxide (selected from a 100–500 µM H<sub>2</sub>O<sub>2</sub> dose range) for 24 h in 100 µL media. Hereafter, media was removed and replaced by media containing 10% AlamarBlue® Cell Viability Reagent (Invitrogen) and further incubated at 37 °C for three hours. The oxidized form

of this Alamar blue (resazurin) enters the cytosol where it is converted into the reduced form (resorufin) by mitochondrial enzyme activity. The amount of resorufin is directly proportional to the amount of proliferating viable cells and was measured fluorescently at 530/590 nm using the Universal Microplate reader FL600 (Bio-TEK instruments Inc., Winooski, VT, USA). Viability was calculated as percent of the difference in reduction of Alamar blue in treated *versus* non-treated cells, corrected for background signal of Alamar blue:  $\text{Viability} = (\text{Ex}-\text{Eblanc})/(\text{Ec}-\text{Eblanc}) \times 100$ ; where Ex = extinction treatment, Ec = Extinction untreated control, and Eblanc = extinction Alamar blue background.

### 3.8. Determination of Cell Amount

The influence of pre- and co-treatment with HO-modulators and effector molecules on cell loss after H<sub>2</sub>O<sub>2</sub>-treatment was determined using PicoGreen dsDNA Quantification reagent (Molecular Probes Inc., Eugene, OR, USA). The amount of double stranded DNA can be quantified using this assay and this correlates to the amount of cells. After measuring the Alamar plate, the media was removed and the plate was washed twice with PBS. Cells were lysated by adding 0.1% Triton X-100 and frozen (−80 °C) and thawed (37 °C) for three consecutive times. The assay was performed according to the protocol of the manufacturer. The fluorescent signal was measured in a FL600 Microplate Fluorescence Reader (Bio-Tek Instruments Inc., Winooski, VT, USA) at excitation 485 nm, emission 520 nm. DNA standards ranging from 0 to 2000 ng DNA/mL were used. The total amount of DNA after treatment was calculated using the standard curve.

### 3.9. Statistical Analysis

Data were analyzed using GraphPad Prism 5.01 software (San Diego, CA, USA). Outliers were tested using the Grubbs' test. In Alamar blue experiments, one outlier was detected in a control untreated group of WT ASCs in two experiments. In picogreen experiments, one outlier was found in a control treated group of WT ASCs and one outlier was found in NAC treated group of HO-2 KO ASCs, in single experiments. Data was analyzed by one- or two-way analysis of variance (ANOVA) with Bonferroni's multiple comparison post test. One-way ANOVA was used in survival studies and picogreen studies and two-way ANOVA was used in other experiments. Results were considered significantly different when  $p < 0.05$  (\*  $p < 0.05$ , \*\*  $p < 0.01$ , and \*\*\*  $p < 0.001$ ).

## 4. Conclusions

Survival from H<sub>2</sub>O<sub>2</sub>-induced apoptosis was similar for WT and HO-2 KO ASCs, suggesting that the HO-2 isoform is not able to provide protection in this specific setting. ASC survival was ameliorated following pre-induction of HO-1 using the cytoprotective flavonoid curcumin. This protection by curcumin was mediated by HO-1 activity since simultaneous inhibition of HO-activity abrogated this curcumin-mediated protection. HO-effector molecules BR/BV did not provide protection, whereas CO protected against H<sub>2</sub>O<sub>2</sub>-induced cell death, suggesting involvement of CO in HO-1 mediated protection. HO-1 pre-induction by curcumin or CO exposure could therefore form a novel promising adjuvant strategy to promote stem cell survival during therapy.

## Supplementary Information

Supplementary materials can be found at <http://www.mdpi.com/1422-0067/15/10/17974/s1>.

## Acknowledgments

This work was supported by grants from the Radboud University Nijmegen Medical Centre, and the Dutch Burns Foundation (# 09.110).

## Author Contributions

Niels A. J. Cremers has been primarily responsible for the acquisition, analysis and interpretation of the data and drafting of the article. He finally approved the version to be published. Stephanie C. M. van Dalen, Rik F. Schelbergen, and Peter L. E. M. van Lent contributed to setting up the isolation and characterization of adipose-derived mesenchymal stem cells. They finally approved the version to be published. Walter A. Szarek was instrumental in providing HO-1 specific activity inhibitors and approved the version to be published. Raymond F. Regan contributed the wild type and HO2 KO mice for our experiments and approved the version to be published. Ditte M. S. Lundvig, Carine E. Carels and Frank A. D. T. G. Wagener have developed the concept of this study and had final responsibility for the design of this study and the subsequent analysis and interpretation of the data. They critically revised the article and finally approved the version to be published.

## Conflicts of Interest

The authors declare no conflict of interest.

## References

1. Leung, A.; Crombleholme, T.M.; Keswani, S.G. Fetal wound healing: Implications for minimal scar formation. *Curr. Opin. Pediatr.* **2012**, *24*, 371–378.
2. Meyer, M.; Muller, A.K.; Yang, J.; Sulcova, J.; Werner, S. The role of chronic inflammation in cutaneous fibrosis: Fibroblast growth factor receptor deficiency in keratinocytes as an example. *J. Investig. Dermatol. Symp. Proc.* **2011**, *15*, 48–52.
3. Butler, K.L.; Goverman, J.; Ma, H.; Fischman, A.; Yu, Y.M.; Bilodeau, M.; Rad, A.M.; Bonab, A.A.; Tompkins, R.G.; Fagan, S.P. Stem cells and burns: Review and therapeutic implications. *J. Burn Care Res.* **2010**, *31*, 874–881.
4. Chen, F.M.; Wu, L.A.; Zhang, M.; Zhang, R.; Sun, H.H. Homing of endogenous stem/progenitor cells for *in situ* tissue regeneration: Promises, strategies, and translational perspectives. *Biomaterials* **2011**, *32*, 3189–3209.
5. Chen, J.S.; Wong, V.W.; Gurtner, G.C. Therapeutic potential of bone marrow-derived mesenchymal stem cells for cutaneous wound healing. *Front. Immunol.* **2012**, *3*, doi:10.3389/fimmu.2012.00192.
6. Maxson, S.; Lopez, E.A.; Yoo, D.; Danilkovitch-Miagkova, A.; Leroux, M.A. Concise review: Role of mesenchymal stem cells in wound repair. *Stem Cells Transl. Med.* **2012**, *1*, 142–149.

7. Aggarwal, S.; Moggio, A.; Bussolati, B. Concise review: Stem/progenitor cells for renal tissue repair: Current knowledge and perspectives. *Stem Cells Transl. Med.* **2013**, *2*, 1011–1019.
8. Bernstein, H.S.; Srivastava, D. Stem cell therapy for cardiac disease. *Pediatr. Res.* **2012**, *71*, 491–499.
9. Sinclair, K.; Yerkovich, S.T.; Chambers, D.C. Mesenchymal stem cells and the lung. *Respirology* **2013**, *18*, 397–411.
10. Sasaki, M.; Abe, R.; Fujita, Y.; Ando, S.; Inokuma, D.; Shimizu, H. Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type. *J. Immunol.* **2008**, *180*, 2581–2587.
11. Fu, X.; Fang, L.; Li, X.; Cheng, B.; Sheng, Z. Enhanced wound-healing quality with bone marrow mesenchymal stem cells autografting after skin injury. *Wound Repair Regen.* **2006**, *14*, 325–335.
12. Liu, Z.J.; Zhuge, Y.; Velazquez, O.C. Trafficking and differentiation of mesenchymal stem cells. *J. Cell. Biochem.* **2009**, *106*, 984–991.
13. Marconi, S.; Bonaconsa, M.; Scambi, I.; Squintani, G.M.; Rui, W.; Turano, E.; Ungaro, D.; D’Agostino, S.; Barbieri, F.; Angiari, S.; *et al.* Systemic treatment with adipose-derived mesenchymal stem cells ameliorates clinical and pathological features in the amyotrophic lateral sclerosis murine model. *Neuroscience* **2013**, *248*, 333–343.
14. Jiang, X.Y.; Lu, D.B.; Jiang, Y.Z.; Zhou, L.N.; Cheng, L.Q.; Chen, B. PGC-1 $\alpha$  prevents apoptosis in adipose-derived stem cells by reducing reactive oxygen species production in a diabetic microenvironment. *Diabetes Res. Clin. Pract.* **2013**, *100*, 368–375.
15. Zuk, P.A. The adipose-derived stem cell: Looking back and looking ahead. *Mol. Biol. Cell* **2010**, *21*, 1783–1787.
16. Mizuno, H.; Tobita, M.; Uysal, A.C. Concise review: Adipose-derived stem cells as a novel tool for future regenerative medicine. *Stem Cells* **2012**, *30*, 804–810.
17. Hamedi-Asl, P.; Halabian, R.; Bahmani, P.; Mohammadipour, M.; Mohammadzadeh, M.; Roushandeh, A.M.; Jahanian-Najafabadi, A.; Kuwahara, Y.; Roudkenar, M.H. Adenovirus-mediated expression of the HO-1 protein within MSCs decreased cytotoxicity and inhibited apoptosis induced by oxidative stresses. *Cell Stress Chaperones* **2012**, *17*, 181–190.
18. Mohammadzadeh, M.; Halabian, R.; Gharehbaghian, A.; Amirizadeh, N.; Jahanian-Najafabadi, A.; Roushandeh, A.M.; Roudkenar, M.H. Nrf-2 overexpression in mesenchymal stem cells reduces oxidative stress-induced apoptosis and cytotoxicity. *Cell Stress Chaperones* **2012**, *17*, 553–565.
19. Halabian, R.; Tehrani, H.A.; Jahanian-Najafabadi, A.; Habibi Roudkenar, M. Lipocalin-2-mediated upregulation of various antioxidants and growth factors protects bone marrow-derived mesenchymal stem cells against unfavorable microenvironments. *Cell Stress Chaperones* **2013**, *18*, 785–800.
20. Zhu, W.; Chen, J.; Cong, X.; Hu, S.; Chen, X. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. *Stem Cells* **2006**, *24*, 416–425.
21. Yagi, H.; Tan, J.; Tuan, R.S. Polyphenols suppress hydrogen peroxide-induced oxidative stress in human bone-marrow derived mesenchymal stem cells. *J. Cell. Biochem.* **2013**, *114*, 1163–1173.

22. McGinley, L.; McMahon, J.; Strappe, P.; Barry, F.; Murphy, M.; O'Toole, D.; O'Brien, T. Lentiviral vector mediated modification of mesenchymal stem cells & enhanced survival in an *in vitro* model of ischaemia. *Stem Cell Res. Ther.* **2011**, *2*, doi:10.1186/scrt53.
23. Xie, X.; Sun, A.; Zhu, W.; Huang, Z.; Hu, X.; Jia, J.; Zou, Y.; Ge, J. Transplantation of mesenchymal stem cells preconditioned with hydrogen sulfide enhances repair of myocardial infarction in rats. *Tohoku J. Exp. Med.* **2012**, *226*, 29–36.
24. Kongpetch, S.; Kukongviriyapan, V.; Prawan, A.; Senggunprai, L.; Kukongviriyapan, U.; Buranrat, B. Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents. *PLoS One* **2012**, *7*, e34994.
25. Wagener, F.A.; Dankers, A.C.; van Summeren, F.; Scharstuhl, A.; van den Heuvel, J.J.; Koenderink, J.B.; Pennings, S.W.; Russel, F.G.; Masereeuw, R. Heme Oxygenase-1 and breast cancer resistance protein protect against heme-induced toxicity. *Curr. Pharm. Des.* **2013**, *19*, 2698–2707.
26. Gozzelino, R.; Jeney, V.; Soares, M.P. Mechanisms of cell protection by heme oxygenase-1. *Ann. Rev. Pharmacol. Toxicol.* **2010**, *50*, 323–354.
27. Morse, D.; Choi, A.M. Heme oxygenase-1: From bench to bedside. *Am. J. Respir. Crit. Care Med.* **2005**, *172*, 660–670.
28. Gozzelino, R.; Soares, M.P. Coupling Heme and Iron Metabolism via Ferritin H Chain. *Antioxid. Redox Signal.* **2013**, *20*, 1754–1769.
29. Wagener, F.A.; Scharstuhl, A.; Tyrrell, R.M.; von den Hoff, J.W.; Jozkowicz, A.; Dulak, J.; Russel, F.G.; Kuijpers-Jagtman, A.M. The heme–heme oxygenase system in wound healing; implications for scar formation. *Curr. Drug Targets* **2010**, *11*, 1571–1585.
30. Burgess, A.P.; Vanella, L.; Bellner, L.; Gotlinger, K.; Falck, J.R.; Abraham, N.G.; Schwartzman, M.L.; Kappas, A. Heme oxygenase (HO-1) rescue of adipocyte dysfunction in HO-2 deficient mice via recruitment of epoxyeicosatrienoic acids (EETs) and adiponectin. *Cell. Physiol. Biochem.* **2012**, *29*, 99–110.
31. Abraham, N.G.; Kappas, A. Pharmacological and clinical aspects of heme oxygenase. *Pharmacol. Rev.* **2008**, *60*, 79–127.
32. Sodhi, K.; Inoue, K.; Gotlinger, K.H.; Canestraro, M.; Vanella, L.; Kim, D.H.; Manthati, V.L.; Koduru, S.R.; Falck, J.R.; Schwartzman, M.L.; *et al.* Epoxyeicosatrienoic acid agonist rescues the metabolic syndrome phenotype of HO-2-null mice. *J. Pharmacol. Exp. Ther.* **2009**, *331*, 906–916.
33. Hou, C.; Shen, L.; Huang, Q.; Mi, J.; Wu, Y.; Yang, M.; Zeng, W.; Li, L.; Chen, W.; Zhu, C. The effect of heme oxygenase-1 complexed with collagen on MSC performance in the treatment of diabetic ischemic ulcer. *Biomaterials* **2013**, *34*, 112–120.
34. Tsubokawa, T.; Yagi, K.; Nakanishi, C.; Zuka, M.; Nohara, A.; Ino, H.; Fujino, N.; Konno, T.; Kawashiri, M.A.; Ishibashi-Ueda, H.; *et al.* Impact of anti-apoptotic and anti-oxidative effects of bone marrow mesenchymal stem cells with transient overexpression of heme oxygenase-1 on myocardial ischemia. *Am. J. Physiol. Heart Circ. Physiol.* **2010**, *298*, H1320–H1329.

35. Jiang, Y.; Chen, L.; Tang, Y.; Ma, G.; Shen, C.; Qi, C.; Zhu, Q.; Yao, Y.; Liu, N. HO-1 gene overexpression enhances the beneficial effects of superparamagnetic iron oxide labeled bone marrow stromal cells transplantation in swine hearts underwent ischemia/reperfusion: An MRI study. *Basic Res. Cardiol.* **2010**, *105*, 431–442.
36. Yang, J.J.; Yang, X.; Liu, Z.Q.; Hu, S.Y.; Du, Z.Y.; Feng, L.L.; Liu, J.F.; Chen, Y.D. Transplantation of adipose tissue-derived stem cells overexpressing heme oxygenase-1 improves functions and remodeling of infarcted myocardium in rabbits. *Tohoku J. Exp. Med.* **2012**, *226*, 231–241.
37. Wojakowski, W.; Tendera, M.; Cybulski, W.; Zuba-Surma, E.K.; Szade, K.; Florczyk, U.; Kozakowska, M.; Szymula, A.; Krzych, L.; Paslawska, U.; *et al.* Effects of intracoronary delivery of allogenic bone marrow-derived stem cells expressing heme oxygenase-1 on myocardial reperfusion injury. *Thromb. Haemost.* **2012**, *108*, 464–475.
38. Liang, O.D.; Mitsialis, S.A.; Chang, M.S.; Vergadi, E.; Lee, C.; Aslam, M.; Fernandez-Gonzalez, A.; Liu, X.; Baveja, R.; Kourembanas, S. Mesenchymal stromal cells expressing heme oxygenase-1 reverse pulmonary hypertension. *Stem Cells* **2011**, *29*, 99–107.
39. Zeng, B.; Chen, H.; Zhu, C.; Ren, X.; Lin, G.; Cao, F. Effects of combined mesenchymal stem cells and heme oxygenase-1 therapy on cardiac performance. *Eur. J. Cardio-Thorac. Surg.* **2008**, *34*, 850–856.
40. Zeng, B.; Lin, G.; Ren, X.; Zhang, Y.; Chen, H. Over-expression of HO-1 on mesenchymal stem cells promotes angiogenesis and improves myocardial function in infarcted myocardium. *J. Biomed. Sci.* **2010**, *17*, 80.
41. Poss, K.D.; Tonegawa, S. Reduced stress defense in heme oxygenase 1-deficient cells. *Proc. Natl. Acad. Sci. USA* **1997**, *94*, 10925–10930.
42. Lin, C.Y.; Peng, C.Y.; Huang, T.T.; Wu, M.L.; Lai, Y.L.; Peng, D.H.; Chen, P.F.; Chen, H.F.; Yen, B.L.; Wu, K.K.; *et al.* Exacerbation of oxidative stress-induced cell death and differentiation in induced pluripotent stem cells lacking heme oxygenase-1. *Stem Cells Dev.* **2012**, *21*, 1675–1687.
43. Basuroy, S.; Bhattacharya, S.; Tcheranova, D.; Qu, Y.; Regan, R.F.; Leffler, C.W.; Parfenova, H. HO-2 provides endogenous protection against oxidative stress and apoptosis caused by TNF- $\alpha$  in cerebral vascular endothelial cells. *Am. J. Physiol. Cell Physiol.* **2006**, *291*, C897–C908.
44. Chen, J.; Regan, R.F. Heme oxygenase-2 gene deletion increases astrocyte vulnerability to hemin. *Biochem. Biophys. Res. Commun.* **2004**, *318*, 88–94.
45. Rogers, B.; Yakopson, V.; Teng, Z.P.; Guo, Y.; Regan, R.F. Heme oxygenase-2 knockout neurons are less vulnerable to hemoglobin toxicity. *Free Radic. Biol. Med.* **2003**, *35*, 872–881.
46. Chen, J.; Tu, Y.; Connolly, E.C.; Ronnett, G.V. Heme oxygenase-2 protects against glutathione depletion-induced neuronal apoptosis mediated by bilirubin and cyclic GMP. *Curr. Neurovasc. Res.* **2005**, *2*, 121–131.
47. Chen, J.; Tu, Y.; Moon, C.; Nagata, E.; Ronnett, G.V. Heme oxygenase-1 and heme oxygenase-2 have distinct roles in the proliferation and survival of olfactory receptor neurons mediated by cGMP and bilirubin, respectively. *J. Neurochem.* **2003**, *85*, 1247–1261.



48. Kim, Y.M.; Choi, B.M.; Kim, Y.S.; Kwon, Y.G.; Kibbe, M.R.; Billiar, T.R.; Tzeng, E. Protective effect of p53 in vascular smooth muscle cells against nitric oxide-induced apoptosis is mediated by up-regulation of heme oxygenase-2. *BMB Rep.* **2008**, *41*, 164–169.
49. Parfenova, H.; Basuroy, S.; Bhattacharya, S.; Tcheranova, D.; Qu, Y.; Regan, R.F.; Leffler, C.W. Glutamate induces oxidative stress and apoptosis in cerebral vascular endothelial cells: Contributions of HO-1 and HO-2 to cytoprotection. *Am. J. Physiol. Cell Physiol.* **2006**, *290*, C1399–C1410.
50. Dore, S.; Takahashi, M.; Ferris, C.D.; Zakhary, R.; Hester, L.D.; Guastella, D.; Snyder, S.H. Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. *Proc. Natl. Acad. Sci. USA* **1999**, *96*, 2445–2450.
51. Dore, S.; Goto, S.; Sampei, K.; Blackshaw, S.; Hester, L.D.; Ingi, T.; Sawa, A.; Traystman, R.J.; Koehler, R.C.; Snyder, S.H. Heme oxygenase-2 acts to prevent neuronal death in brain cultures and following transient cerebral ischemia. *Neuroscience* **2000**, *99*, 587–592.
52. Ter Huurne, M.; Schelbergen, R.; Blattes, R.; Blom, A.; de Munter, W.; Grevers, L.C.; Jeanson, J.; Noel, D.; Casteilla, L.; Jorgensen, C.; *et al.* Antiinflammatory and chondroprotective effects of intraarticular injection of adipose-derived stem cells in experimental osteoarthritis. *Arthritis Rheumatol.* **2012**, *64*, 3604–3613.
53. Zheng, B.; Cao, B.; Li, G.; Huard, J. Mouse adipose-derived stem cells undergo multilineage differentiation *in vitro* but primarily osteogenic and chondrogenic differentiation *in vivo*. *Tissue Eng.* **2006**, *12*, 1891–1901.
54. Kolf, C.M.; Cho, E.; Tuan, R.S. Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: Regulation of niche, self-renewal and differentiation. *Arthritis Res. Ther.* **2007**, *9*, doi:10.1186/ar2116.
55. Cawthorn, W.P.; Scheller, E.L.; MacDougald, O.A. Adipose tissue stem cells meet preadipocyte commitment: Going back to the future. *J. Lipid Res.* **2012**, *53*, 227–246.
56. Yamamoto, N.; Akamatsu, H.; Hasegawa, S.; Yamada, T.; Nakata, S.; Ohkuma, M.; Miyachi, E.; Marunouchi, T.; Matsunaga, K. Isolation of multipotent stem cells from mouse adipose tissue. *J. Dermatol. Sci.* **2007**, *48*, 43–52.
57. Nakagami, H.; Maeda, K.; Morishita, R.; Iguchi, S.; Nishikawa, T.; Takami, Y.; Kikuchi, Y.; Saito, Y.; Tamai, K.; Ogihara, T.; *et al.* Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. *Arterioscler. Thromb. Vasc. Biol.* **2005**, *25*, 2542–2547.
58. Sung, J.H.; Yang, H.M.; Park, J.B.; Choi, G.S.; Joh, J.W.; Kwon, C.H.; Chun, J.M.; Lee, S.K.; Kim, S.J. Isolation and characterization of mouse mesenchymal stem cells. *Transplant. Proc.* **2008**, *40*, 2649–2654.
59. Wang, L.; Huang, H.; Fan, Y.; Kong, B.; Hu, H.; Hu, K.; Guo, J.; Mei, Y.; Liu, W.L. Effects of Downregulation of MicroRNA-181a on H<sub>2</sub>O<sub>2</sub>-Induced H9c2 Cell Apoptosis via the Mitochondrial Apoptotic Pathway. *Oxid. Med. Cell. Longev.* **2014**, *2014*, 960362, doi:10.1155/2014/960362.
60. Kou, X.; Shen, K.; An, Y.; Qi, S.; Dai, W.X.; Yin, Z. Ampelopsin inhibits H<sub>2</sub>O<sub>2</sub>-induced apoptosis by ERK and Akt signaling pathways and up-regulation of heme oxygenase-1. *Phytother. Res. PTR* **2012**, *26*, 988–994.

61. Wang, F.W.; Wang, Z.; Zhang, Y.M.; Du, Z.X.; Zhang, X.L.; Liu, Q.; Guo, Y.J.; Li, X.G.; Hao, A.J. Protective effect of melatonin on bone marrow mesenchymal stem cells against hydrogen peroxide-induced apoptosis *in vitro*. *J. Cell. Biochem.* **2013**, *114*, 2346–2355.
62. Scharstuhl, A.; Mutsaers, H.A.; Pennings, S.W.; Szarek, W.A.; Russel, F.G.; Wagener, F.A. Curcumin-induced fibroblast apoptosis and *in vitro* wound contraction are regulated by antioxidants and heme oxygenase: Implications for scar formation. *J. Cell. Mol. Med.* **2009**, *13*, 712–725.
63. Zeng, B.; Ren, X.; Lin, G.; Zhu, C.; Chen, H.; Yin, J.; Jiang, H.; Yang, B.; Ding, D. Paracrine action of HO-1-modified mesenchymal stem cells mediates cardiac protection and functional improvement. *Cell Biol. Int.* **2008**, *32*, 1256–1264.
64. Masoud, M.S.; Anwar, S.S.; Afzal, M.Z.; Mehmood, A.; Khan, S.N.; Riazuddin, S. Pre-conditioned mesenchymal stem cells ameliorate renal ischemic injury in rats by augmented survival and engraftment. *J. Transl. Med.* **2012**, *10*, doi:10.1186/1479-5876-10-243.
65. Loboda, A.; Was, H.; Jozkowicz, A.; Dulak, J. Janus face of Nrf2-HO-1 axis in cancer—friend in chemoprevention, foe in anticancer therapy. *Lung Cancer* **2008**, *60*, 1–3.
66. Alcaraz, M.J.; Habib, A.; Lebret, M.; Creminon, C.; Levy-Toledano, S.; Maclouf, J. Enhanced expression of haem oxygenase-1 by nitric oxide and antiinflammatory drugs in NIH 3T3 fibroblasts. *Br. J. Pharmacol.* **2000**, *130*, 57–64.
67. Zhang, Q.H.; Zhou, Z.S.; Lu, G.S.; Song, B.; Guo, J.X. Melatonin improves bladder symptoms and may ameliorate bladder damage via increasing HO-1 in rats. *Inflammation* **2013**, *36*, 651–657.
68. Hatcher, H.; Planalp, R.; Cho, J.; Torti, F.M.; Torti, S.V. Curcumin: From ancient medicine to current clinical trials. *Cell. Mol. Life Sci. CMLS* **2008**, *65*, 1631–1652.
69. Epstein, J.; Sanderson, I.R.; Macdonald, T.T. Curcumin as a therapeutic agent: The evidence from *in vitro*, animal and human studies. *Br. J. Nutr.* **2010**, *103*, 1545–1557.
70. Motterlini, R.; Foresti, R.; Bassi, R.; Green, C.J. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. *Free Radic. Biol. Med.* **2000**, *28*, 1303–1312.
71. Aggarwal, B.B.; Sundaram, C.; Malani, N.; Ichikawa, H. Curcumin: The Indian solid gold. *Adv. Exp. Med. Biol.* **2007**, *595*, 1–75.
72. Prasad, S.; Gupta, S.C.; Tyagi, A.K.; Aggarwal, B.B. Curcumin, a component of golden spice: From bedside to bench and back. *Biotechnol. Adv.* **2014**, *32*, 1053–1064.
73. Zhou, H.; Beevers, C.S.; Huang, S. The targets of curcumin. *Curr. Drug Targets* **2011**, *12*, 332–347.
74. Sugishima, M.; Higashimoto, Y.; Oishi, T.; Takahashi, H.; Sakamoto, H.; Noguchi, M.; Fukuyama, K. X-ray crystallographic and biochemical characterization of the inhibitory action of an imidazole-dioxolane compound on heme oxygenase. *Biochemistry* **2007**, *46*, 1860–1867.
75. Kinobe, R.T.; Vlahakis, J.Z.; Vreman, H.J.; Stevenson, D.K.; Brien, J.F.; Szarek, W.A.; Nakatsu, K. Selectivity of imidazole-dioxolane compounds for *in vitro* inhibition of microsomal haem oxygenase isoforms. *Br. J. Pharmacol.* **2006**, *147*, 307–315.

76. Rahman, M.N.; Vlahakis, J.Z.; Szarek, W.A.; Nakatsu, K.; Jia, Z. X-ray crystal structure of human heme oxygenase-1 in complex with 1-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanone: A common binding mode for imidazole-based heme oxygenase-1 inhibitors. *J. Med. Chem.* **2008**, *51*, 5943–5952.
77. Vlahakis, J.Z.; Kinobe, R.T.; Bowers, R.J.; Brien, J.F.; Nakatsu, K.; Szarek, W.A. Synthesis and evaluation of azalanstat analogues as heme oxygenase inhibitors. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 1457–1461.
78. Lin, H.Y.; Shen, S.C.; Lin, C.W.; Yang, L.Y.; Chen, Y.C. Baicalein inhibition of hydrogen peroxide-induced apoptosis via ROS-dependent heme oxygenase 1 gene expression. *Biochim. Biophys. Acta* **2007**, *1773*, 1073–1086.
79. Zhang, M.; Zhang, B.H.; Chen, L.; An, W. Overexpression of heme oxygenase-1 protects smooth muscle cells against oxidative injury and inhibits cell proliferation. *Cell Res.* **2002**, *12*, 123–132.
80. Fu, Y.Q.; Fang, F.; Lu, Z.Y.; Kuang, F.W.; Xu, F. *N*-Acetylcysteine protects alveolar epithelial cells from hydrogen peroxide-induced apoptosis through scavenging reactive oxygen species and suppressing c-Jun *N*-terminal kinase. *Exp. Lung Res.* **2010**, *36*, 352–361.
81. Samuni, Y.; Goldstein, S.; Dean, O.M.; Berk, M. The chemistry and biological activities of *N*-acetylcysteine. *Biochim. Biophys. Acta* **2013**, *1830*, 4117–4129.
82. Fernandez-Checa, J.C.; Garcia-Ruiz, C.; Colell, A.; Morales, A.; Mari, M.; Miranda, M.; Ardite, E. Oxidative stress: Role of mitochondria and protection by glutathione. *Biofactors* **1998**, *8*, 7–11.
83. Fernandez-Checa, J.C.; Kaplowitz, N.; Garcia-Ruiz, C.; Colell, A.; Miranda, M.; Mari, M.; Ardite, E.; Morales, A. GSH transport in mitochondria: Defense against TNF-induced oxidative stress and alcohol-induced defect. *Am. J. Physiol.* **1997**, *273*, G7–G17.
84. Sedlak, T.W.; Saleh, M.; Higginson, D.S.; Paul, B.D.; Juluri, K.R.; Snyder, S.H. Bilirubin and glutathione have complementary antioxidant and cytoprotective roles. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 5171–5176.
85. Aronis, A.; Aharoni-Simon, M.; Madar, Z.; Tirosh, O. Triacylglycerol-induced impairment in mitochondrial biogenesis and function in J774.2 and mouse peritoneal macrophage foam cells. *Arch. Biochem. Biophys.* **2009**, *492*, 74–81.
86. Bruggisser, R.; von Daeniken, K.; Jundt, G.; Schaffner, W.; Tullberg-Reinert, H. Interference of plant extracts, phytoestrogens and antioxidants with the MTT tetrazolium assay. *Planta Med.* **2002**, *68*, 445–448.
87. Krifka, S.; Hiller, K.A.; Spagnuolo, G.; Jewett, A.; Schmalz, G.; Schweikl, H. The influence of glutathione on redox regulation by antioxidant proteins and apoptosis in macrophages exposed to 2-hydroxyethyl methacrylate (HEMA). *Biomaterials* **2012**, *33*, 5177–5186.
88. Xiong, L.; Sun, J.; Hirche, C.; Yang, J.; Yang, Y.; Xia, Y.; Lehnhardt, M.; Wang, R.; Fu, X. *In vitro* *N*-acetyl-L-cysteine promotes proliferation and suppresses interleukin-8 expression in adipose-derived stem cells. *Aesthet. Plast. Surg.* **2012**, *36*, 1260–1265.
89. Ji, H.; Liu, Y.; Zhao, X.; Zhang, M. *N*-acetyl-L-cysteine enhances the osteogenic differentiation and inhibits the adipogenic differentiation through up regulation of Wnt 5a and down regulation of PPARγ in bone marrow stromal cells. *Biomed. Pharmacother.* **2011**, *65*, 369–374.

90. Park, C.; So, H.S.; Shin, C.H.; Baek, S.H.; Moon, B.S.; Shin, S.H.; Lee, H.S.; Lee, D.W.; Park, R. Quercetin protects the hydrogen peroxide-induced apoptosis via inhibition of mitochondrial dysfunction in H9c2 cardiomyoblast cells. *Biochem. Pharmacol.* **2003**, *66*, 1287–1295.
91. Singh, M.; Sharma, H.; Singh, N. Hydrogen peroxide induces apoptosis in HeLa cells through mitochondrial pathway. *Mitochondrion* **2007**, *7*, 367–373.
92. Qian, Y.; Du, Y.H.; Tang, Y.B.; Lv, X.F.; Liu, J.; Zhou, J.G.; Guan, Y.Y. ClC-3 chloride channel prevents apoptosis induced by hydrogen peroxide in basilar artery smooth muscle cells through mitochondria dependent pathway. *Apoptosis* **2011**, *16*, 468–477.
93. Liu, N.S.; Du, X.; Lu, J.; He, B.P. Diva reduces cell death in response to oxidative stress and cytotoxicity. *PLoS One* **2012**, *7*, e43180.
94. Chen, H.Y.; Zhang, X.; Chen, S.F.; Zhang, Y.X.; Liu, Y.H.; Ma, L.L.; Wang, L.X. The protective effect of 17 $\beta$ -estradiol against hydrogen peroxide-induced apoptosis on mesenchymal stem cell. *Biomed. Pharmacother.* **2012**, *66*, 57–63.
95. Wei, H.; Li, Z.; Hu, S.; Chen, X.; Cong, X. Apoptosis of mesenchymal stem cells induced by hydrogen peroxide concerns both endoplasmic reticulum stress and mitochondrial death pathway through regulation of caspases, p38 and JNK. *J. Cell. Biochem.* **2010**, *111*, 967–978.
96. Lee, S.J.; Ryter, S.W.; Xu, J.F.; Nakahira, K.; Kim, H.P.; Choi, A.M.K.; Kim, Y.S. Carbon monoxide activates autophagy via mitochondrial reactive oxygen species formation. *Am. J. Respir. Cell Mol.* **2011**, *45*, 867–873.
97. Choi, Y.K.; Por, E.D.; Kwon, Y.G.; Kim, Y.M. Regulation of ROS production and vascular function by carbon monoxide. *Oxid. Med. Cell. Longev.* **2012**, *2012*, doi:10.1155/2012/794237.
98. Piantadosi, C.A. Carbon monoxide, reactive oxygen signaling, and oxidative stress. *Free Radic. Biol. Med.* **2008**, *45*, 562–569.
99. Chi, P.L.; Liu, C.J.; Lee, I.T.; Chen, Y.W.; Hsiao, L.D.; Yang, C.M. HO-1 induction by CO-RM2 attenuates TNF- $\alpha$ -induced cytosolic phospholipase A2 expression via inhibition of PKC $\alpha$ -dependent NADPH oxidase/ROS and NF- $\kappa$ B. *Med. Inflamm.* **2014**, *2014*, 279171, doi:10.1155/2014/279171.
100. Kim, H.J.; Zheng, M.; Kim, S.K.; Cho, J.J.; Shin, C.H.; Joe, Y.; Chung, H.T. CO/HO-1 Induces NQO-1 Expression via Nrf2 Activation. *Immune Netw.* **2011**, *11*, 376–382.
101. Lee, B.S.; Heo, J.; Kim, Y.M.; Shim, S.M.; Pae, H.O.; Kim, Y.M.; Chung, H.T. Carbon monoxide mediates heme oxygenase 1 induction via Nrf2 activation in hepatoma cells. *Biochem. Biophys. Res. Commun.* **2006**, *343*, 965–972.
102. Kim, H.P.; Choi, A.M. A new road to induce heme oxygenase-1 expression by carbon monoxide. *Circ. Res.* **2007**, *101*, 862–864.
103. Ozaki, K.S.; Kimura, S.; Murase, N. Use of carbon monoxide in minimizing ischemia reperfusion injury in transplantation. *Transpl. Rev.* **2012**, *26*, 125–139.
104. Bilban, M.; Haschemi, A.; Wegiel, B.; Chin, B.Y.; Wagner, O.; Otterbein, L.E. Heme oxygenase and carbon monoxide initiate homeostatic signaling. *J. Mol. Med.* **2008**, *86*, 267–279.
105. Heo, J.M.; Kim, H.J.; Ha, Y.M.; Park, M.K.; Kang, Y.J.; Lee, Y.S.; Seo, H.G.; Lee, J.H.; Yun-Choi, H.S.; Chang, K.C. YS 51, 1-( $\beta$ -naphthylmethyl)-6,7-dihydroxy-1,2,3,4,-tetrahydroisoquinoline, protects endothelial cells against hydrogen peroxide-induced injury via carbon monoxide derived from heme oxygenase-1. *Biochem. Pharmacol.* **2007**, *74*, 1361–1370.

106. Wei, L.; Fraser, J.L.; Lu, Z.Y.; Hu, X.; Yu, S.P. Transplantation of hypoxia preconditioned bone marrow mesenchymal stem cells enhances angiogenesis and neurogenesis after cerebral ischemia in rats. *Neurobiol. Dis.* **2012**, *46*, 635–645.
107. Malgieri, A.; Kantzari, E.; Patrizi, M.P.; Gambardella, S. Bone marrow and umbilical cord blood human mesenchymal stem cells: State of the art. *Int. J. Clin. Exp. Med.* **2010**, *3*, 248–269.
108. Tse, W.T.; Pendleton, J.D.; Beyer, W.M.; Egalka, M.C.; Guinan, E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: Implications in transplantation. *Transplantation* **2003**, *75*, 389–397.
109. Shin, L.; Peterson, D.A. Human mesenchymal stem cell grafts enhance normal and impaired wound healing by recruiting existing endogenous tissue stem/progenitor cells. *Stem Cells Transl. Med.* **2013**, *2*, 33–42.
110. Tang, Y.L.; Tang, Y.; Zhang, Y.C.; Qian, K.; Shen, L.; Phillips, M.I. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. *J. Am. Coll. Cardiol.* **2005**, *46*, 1339–1350.
111. Caplan, A.I.; Correa, D. The MSC: An injury drugstore. *Cell Stem Cell* **2011**, *9*, 11–15.
112. Herrmann, J.L.; Abarbanell, A.M.; Weil, B.R.; Manukyan, M.C.; Poynter, J.A.; Brewster, B.J.; Wang, Y.; Meldrum, D.R. Optimizing stem cell function for the treatment of ischemic heart disease. *J. Surg. Res.* **2011**, *166*, 138–145.
113. Di Francesco, L.; Totani, L.; Dovizio, M.; Piccoli, A.; di Francesco, A.; Salvatore, T.; Pandolfi, A.; Evangelista, V.; Dercho, R.A.; Seta, F.; *et al.* Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor- $\alpha$  biosynthesis via heme oxygenase-1 in human endothelial cells. *Circ. Res.* **2009**, *104*, 506–513.
114. Bellner, L.; Martinelli, L.; Halilovic, A.; Patil, K.; Puri, N.; Dunn, M.W.; Regan, R.F.; Schwartzman, M.L. Heme oxygenase-2 deletion causes endothelial cell activation marked by oxidative stress, inflammation, and angiogenesis. *J. Pharmacol. Exp. Ther.* **2009**, *331*, 925–932.